Human PilotPubMed ID: 40131143·2025

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee KY, Burgess MM.

Alternative Therapies in Health and Medicine, 2025 · n = 2

Key finding

Intravenous BPC-157 up to 20mg was well-tolerated in 2 healthy adults with no measurable effects on heart, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours.

Summary

IRB-approved pilot study administering IV BPC-157 (10mg day 1, 20mg day 2) to two healthy adults. No adverse events or clinically meaningful changes in vital signs, ECG, or laboratory biomarkers were observed.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

BPC-157L2

A gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. Despite over 100 preclinical studies, human clinical data remains extremely limited.

More research on BPC-157

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

Sports Health · 2025 · Review

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

Pharmaceuticals · 2024 · Review

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

Frontiers in Pharmacology · 2021 · Review

Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway

Scientific Reports · 2020 · Animal Study

Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts

Molecules · 2014 · In Vitro